Aims To perform a systematic review of the published literature to examine the efficacy of interventions in improving quality of life outcomes of patients with malignant pleural effusion.

Methods Five electronic databases were systematically searched and assessed. We included all studies evaluating HRQOL outcomes for the following interventions: therapeutic thoracocentesis, talc slurry pleurodesis (TS), indwelling pleural catheter insertion (IPC) and thoracoscopic talc poudrage pleurodesis (TTP). Meta-analysis was not performed due to substantial heterogeneity in the published data.

Results Of 56 abstracts, 16 were included in the review, all of which reported HRQOL outcomes as a secondary endpoint. Six of these studies were randomised controlled trials (RCTs) with two considered very good quality. One eligible study on therapeutic thoracocentesis outcomes was identified. 880 patients in eight studies received TTP; 475 patients in six studies received TS; 750 patients in eight studies underwent IPC insertion. TTP, TS and IPCs were all associated with modest but inconsistent improvements in HRQOL up to 12 weeks. In eight comparative studies (both randomised and non-randomised data), no intervention was significantly different to another in HRQOL outcomes at any time point. The attrition to follow up was 47.3% (582/1228) at three months.

Conclusion To our knowledge, this is the first study to systematically review the evidence for HRQOL outcomes following invasive pleural interventions for malignant pleural effusion. TTP, TS and IPCs seem to improve HRQOL in MPE over 4 to 12 weeks, but there is insufficient longer term data due to high attrition rates. Evidence for the most effective treatment strategy is limited by the small number of randomised or comparative studies.

REFERENCE

Poster sessions

P237 PLEURAL ABNORMALITIES PREDATING THE DEVELOPMENT OF MESOTHELIOMA

M Hassan, R Asciak, RJ Halifax, R Mercer, NM Rahman. Oxford Centre for Respiratory Medicine, Oxford University Hospitals, Oxford, UK

Background Mesothelioma is an aggressive tumour of the pleura that is closely related to asbestos exposure. Asbestos is known to cause benign pleural thickening, effusion and plaques and the majority of patients with these abnormalities do not develop mesothelioma. It has been noted, however, that asbestos-exposed patients who have pleural plaques are at increased risk of mesothelioma.[1] This study aimed to describe the range of pleural abnormalities seen on CT done at some time before the diagnosis of mesothelioma was made.

Methods Electronic radiological records of all patients who were diagnosed with mesothelioma in the trust from 2009 till June 2017 were screened for any chest CT (or abdomen CT with at least half of the thorax imaged) obtained at least 6 months prior to the CT that triggered the diagnosis of mesothelioma. CTs were examined for the presence of pleural plaques, thickening, nodules and/or effusion. CT studies were divided into 3 time periods: within one year (A), 1–3 years before (B), and more than 3 years before (C) the diagnostic CT.

Results 170 patients were screened. 39 patients had one or more pre-diagnosis CTs. A total of 53 CTs were available for comparison. Effusion was the most common abnormality seen in 23/53 CTs followed by thickening seen in 17/53, then plaques 15/53 and pleural nodules in 5/53. Four nodules (2 in period A and 2 in period B) progressed to tumour later on. Effusion was seen in 50% of studies from periods A and B. Pleural thickening and plaques were noticeable in around 40% of CTs from periods A and B. 13 studies did not show any pleural abnormality (3 studies in period A, 4 in period B and 6 in period C).

Conclusion Mesothelioma is a rapidly progressive disease that can be difficult to track in radiological studies done before clinical presentation. Pleural effusion, followed by smooth thickening and plaques, are fairly common abnormalities in pre-diagnosis CTs.

REFERENCE